Activity of second‐generation ALK inhibitors against crizotinib‐resistant mutants in an NPM‐ALK model compared to EML4‐ALK
Diletta Fontana(University of Milano-Bicocca), Luca Mologni(University of Milano-Bicocca)
Cited by 88
Related Papers
Inhibition of RET tyrosine kinase by SU5416
|Journal of Molecular Endocrinology|2006|54
ETNK1 mutations induce a mutator phenotype that can be reverted with phosphoethanolamine
|Nature Communications|2020|49
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922
|Oncotarget|2015|33